While the first wave of response to the COVID-19 pandemic is unlikely to have biomedical tools available to it, preparations should now be made to ensure eventual equitable access to vaccines and antivirals. For influenza, vaccination and anti-virals are almost entirely absent in LDCs, who shoulder an enormous burden of the up to 500,000 estimated annual global deaths due to seasonal influenza.